Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer

Anti-Cancer Drugs

Volumn 10, Issue 2, 1999, Pages 155-162

  Possinger, K ^a   Kaufmann, M ^b   Coleman, R ^c   Stuart, N S A ^d   Helsing, M ^e   Ohnmacht, U ^f   Arning, M ^f  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c WESTON PARK HOSPITAL   (United Kingdom)

^d YSBYTY GWYNEDD   (United Kingdom)

^e Regional Hospital Orebo   (Sweden)

^f LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

Advanced breast cancer; First line therapy; Gemcitabine

Indexed keywords

ALANINE AMINOTRANSFERASE; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANAPHYLAXIS; ANEMIA; ARTICLE; ASTHENIA; BLOOD CLOTTING DISORDER; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLLAPSE; DIARRHEA; DRUG EFFICACY; DYSPNEA; FEMALE; FLU LIKE SYNDROME; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LIVER TOXICITY; MULTICENTER STUDY; NAUSEA; NEUTROPHIL; PAIN; PERICARDITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; VISUAL DISORDER; VOMITING;

EID: 0032999571     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199902000-00003     Document Type: Article

References (24)

1. Rubens RD. Improving treatment for advanced breast cancer. Cancer Surv Breast Cancer 1993; 18: 199-209.
2. Holmes FA, Walters RS, Theriault RL, et al. Phase II trial of Taxol, an active new drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 83: 1797-805.
3. Launchbury AP, Habboubi N. Epirubicin and doxorubicin: a comparison of their characteristics therapeutic activity and toxicity. Cancer Treat Rev 1993; 19: 197-228.
4. Lund B, Hansen OP, Theilade K, et al. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine in previously treated ovarian cancer. J Natl Cancer Inst 1994; 86: 1530-3.
5. Cormier Y, Eisenhauser E, Muldal A, et al. Gemcitabine is an active agent in previously untreated extensive small cell lung cancer. A study of National Cancer Institute of Canada Clinical Treatment Group. Ann Oncol 1994; 5: 283-5.
6. Anderson LH, Lund B, Bach F, et al. Single agent activity of weekly gemcitabine in advanced non-small cell lung cancer. A phase II study. J Clin Oncol 1994; 12: 1821-6.
7. Gatzemeier M, Shepherd FA, Le Chevalier T, et al. Activity of gemcitabine in non-small cell lung cancer. A multicentre extended phase II study. Eur J Cancer 1996; 32: 243-8.
8. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2′,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 12: 29-34.
9. Carmichael J, Fink U, Russel RCG, et al Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996; 73: 101-5.
10. Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995; 13: 2731-6.
11. Carmichael J, Walling J. Phase II activity of gemcitabine in advanced breast cancer. Semin Oncol 1996; 23 (suppl 10): 77-81.
12. Catimel G, Vermorken JB, Clavel M, et al. A phase II study of gemcitabine (LY188011) in patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994; 5: 543-7.
13. Pollera CF, Ceribelli A, Crecco M, Calabresi M. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 1994; 5: 182-4.
14. Tonato M, Mosconi AM, Martin C. Safety profile of gemcitabine. Anti-Cancer Drugs 1995; 6: 27-32.
15. Green MR. Gemcitabine safety overview. Semin Oncol 1996; 23 (suppl 10): 32-5.
16. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization of Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
17. Efron B. Censored data and the bootstrap. J Am Stat Ass 1981; 76: 312-9.
18. Possinger K. Gemcitabine in advanced breast cancer. Anti-Cancer Drugs 1995; 6 (suppl 6): 55-9.
19. Blackstein M, Vogel CL, Ambinder R, et al. Phase II study of gemcitabine in patients with metastatic breast cancer. Eur J Cancer 1997; 33: S149 (abstr 664).
20. Spielmann M, Pouillart P, Espie M, et al. Activity of gemcitabine in metastatic breast cancer (MBC) patients previously treated with anthracycline-containing regimens. Eur J Cancer 1997; 33: S149 (abstr 663).
21. Hortobagyi GN, Holmes FA, Ibrahim N, Champlin R, Buzdas AU. The University of Texas MD Anderson Cancer center experience with paclitaxel in breast cancer. Semin Oncol 1997; 24 (suppl 3): 30-3.
22. Klaassen U, Diergarten K, Ditrich CH, et al. Randomised trial of 2 doses of taxol in metastatic breast cancer. An interim analysis. Oncologie 1994; 17: 86-90.
23. Perez-Manga G, Lluch A, Garcia-Conde J, et al. High activity of gemcitabine in combination with doxorubicin in advanced breast cancer: preliminary results from an early phase II study. Proc Am Soc Clin Oncol 1997; 16: 147a (abstr 515).
24. Sanchez-Roviva P, Mohedano N, Moreno MA, et al. Preliminary results from an early phase II combination of gemcitabine and taxol in metastatic breast cancer. Eur J Cancer 1997; 33: S154 (abstr 685).